Why BioCryst Pharmaceuticals Stock Is Soaring Today

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were soaring 14.5% higher as of 10:51 a.m. EDT on Thursday. BioCryst stated that the majority of these sales came from new patients who switched to Orladeyo from other medications or from acute-only treatment. In addition to its better-than-expected sales, BioCryst also announced that it's reached an agreement with the U.S. Food and Drug Administration (FDA) to use change from baseline in hemoglobin as the primary endpoint for its planned pivotal clinical studies evaluating BCX9930 in treating rare disease paroxysmal nocturnal hemoglobinuria (PNH).